Phenotypes associated with this allele

• Allele Symbol: Mapk14^tm1.1Dvb
• Allele Name: targeted mutation 1.1, Dmitry V Bulavin
• Allele ID: MGI:3706998
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Mapk14^tm1.1Dvb/Mapk14^tm1.1Dvb	B6(FVB)-Mapk14^tm1.1Dvb	MGI:5500172
ht2	Mapk14^tm1.1Dvb/Mapk14^+	B6(FVB)-Mapk14^tm1.1Dvb	MGI:5500173
cx3	Mapk14^tm1.1Dvb/Mapk14^+ Ppm1d^tm1Lad/Ppm1d^tm1Lad Tg(IghMyc)22Bri/0	involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL	MGI:3710181
cx4	Mapk14^tm1.1Dvb/Mapk14^+ Ppm1d^tm1Lad/Ppm1d^tm1Lad	involves: 129S7/SvEvBrd * C57BL/6	MGI:5500175

Genotype
MGI:5500172

hm1

• Allelic Composition: Mapk14^tm1.1Dvb/Mapk14^tm1.1Dvb
• Genetic Background: B6(FVB)-Mapk14^tm1.1Dvb

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

embryonic lethality during organogenesis ( J:151980 )

• embryos die by E11.5 as a result of placental and heart defects

Genotype
MGI:5500173

ht2

• Allelic Composition: Mapk14^tm1.1Dvb/Mapk14⁺
• Genetic Background: B6(FVB)-Mapk14^tm1.1Dvb

cellular

decreased pancreatic beta cell proliferation ( J:151980 )

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 4-6 month old mice (11 weeks post treatment) as compared to wild-type

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 9-14 month old mice (7 weeks post treatment) as compared to wild-type

increased pancreatic beta cell proliferation ( J:151980 )

• islet cell proliferation is increased in 10-12 month old mutant mice at 3 and at 30 days post-STZ treatment as compared to wild-type

endocrine/exocrine glands

decreased pancreatic beta cell proliferation ( J:151980 )

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 4-6 month old mice (11 weeks post treatment) as compared to wild-type

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 9-14 month old mice (7 weeks post treatment) as compared to wild-type

increased pancreatic beta cell proliferation ( J:151980 )

• islet cell proliferation is increased in 10-12 month old mutant mice at 3 and at 30 days post-STZ treatment as compared to wild-type

homeostasis/metabolism

decreased circulating glucose level ( J:151980 )

• pancreatic islet proliferation is decreased in aged (22-24 month old) mice, but is similar to wild-type in young mice

Genotype
MGI:3710181

cx3

• Allelic Composition: Mapk14^tm1.1Dvb/Mapk14⁺; Ppm1d^tm1Lad/Ppm1d^tm1Lad; Tg(IghMyc)22Bri/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL

mortality/aging

premature death ( J:120284 )

• the median lifespan of 130 days

neoplasm

decreased tumor incidence ( J:120284 )

• similar to mice carrying double Ppm1d^tm1Lad allele without Mapk14^tm1Dvb allele, based on increased median survival time, mice carrying single Mapk14^tm1Dvb allele were considerably more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d⁺ allele

Genotype
MGI:5500175

cx4

• Allelic Composition: Mapk14^tm1.1Dvb/Mapk14⁺; Ppm1d^tm1Lad/Ppm1d^tm1Lad
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

cellular

cellular phenotype ( J:151980 )

N • double mutant Ppm1d^tm1Lad Mapk14^tm1.1Dvb mice exhibit pancreatic islet proliferation similar to wild-type, correcting the phenotype observed in Ppm1d^tm1Lad mutant mice

N • double mutant Ppm1d^tm1Lad Mapk14^tm1.1Dvb mice do not exhibit impaired glucose tolerance, correcting the phenotype observed in Ppm1d^tm1Lad/ mutant mice